Search Page

1

Cite

Share

American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G. Witt DM, et al. Among authors: crowther ma. Blood Adv. 2018 Nov 27;2(22):3257-3291. doi: 10.1182/bloodadvances.2018024893. Blood Adv. 2018. PMID: 30482765 Free PMC article.

Cite

Share

2

Cite

Share

Venous thromboembolism prophylaxis in critically ill patients.

Boonyawat K, Crowther MA. Boonyawat K, et al. Among authors: crowther ma. Semin Thromb Hemost. 2015 Feb;41(1):68-74. doi: 10.1055/s-0034-1398386. Epub 2015 Jan 16. Semin Thromb Hemost. 2015. PMID: 25594495 Review.

Cite

Share

3

Cite

Share

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. Neunert C, et al. Among authors: crowther ma. Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984. Epub 2011 Feb 16. Blood. 2011. PMID: 21325604 Free article. Review.

Cite

Share

4

Cite

Share

Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.

Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, Carrier M, Crowther MA, Ghosh I, Lazo-Langner A, Zondag M; Study Investigators. Schulman S, et al. Among authors: crowther ma. Thromb Haemost. 2018 May;118(5):842-851. doi: 10.1055/s-0038-1636541. Epub 2018 Mar 21. Thromb Haemost. 2018. PMID: 29564837

Cite

Share

5

Cite

Share

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Siegal DM, et al. Among authors: crowther ma. N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11. N Engl J Med. 2015. PMID: 26559317 Free article. Clinical Trial.

Cite

Share

6

Cite

Share

Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study.

Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, Wu C, Nazi I, Crowther MA. Linkins LA, et al. Among authors: crowther ma. J Thromb Haemost. 2016 Jun;14(6):1206-10. doi: 10.1111/jth.13330. Epub 2016 May 10. J Thromb Haemost. 2016. PMID: 27061271 Free article. Clinical Trial.

Cite

Share

7

Cite

Share

Systematic review and meta-analysis methodology.

Crowther M, Lim W, Crowther MA. Crowther M, et al. Among authors: crowther ma. Blood. 2010 Oct 28;116(17):3140-6. doi: 10.1182/blood-2010-05-280883. Epub 2010 Jul 23. Blood. 2010. PMID: 20656933 Free article. Review.

Cite

Share

8

Cite

Share

Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism.

Crowther MA, Cuker A. Crowther MA, et al. N Engl J Med. 2017 Mar 30;376(13):1279-1280. doi: 10.1056/NEJMe1701628. Epub 2017 Mar 18. N Engl J Med. 2017. PMID: 28316277 No abstract available.

Cite

Share

9

Cite

Share

Evidence-based guidelines--an introduction.

Lim W, Arnold DM, Bachanova V, Haspel RL, Rosovsky RP, Shustov AR, Crowther MA. Lim W, et al. Among authors: crowther ma. Hematology Am Soc Hematol Educ Program. 2008:26-30. doi: 10.1182/asheducation-2008.1.26. Hematology Am Soc Hematol Educ Program. 2008. PMID: 19074050

Cite

Share

10

Cite

Share

Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.

Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, Gavriilaki E, Alluri R, Streiff MB, Petri M, Crowther MA, McCrae KR, Brodsky RA. Chaturvedi S, et al. Among authors: crowther ma. Blood. 2020 Jan 23;135(4):239-251. doi: 10.1182/blood.2019003863. Blood. 2020. PMID: 31812994 Free PMC article.

Cite

Share